We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
DTRT Health Acquisition Corporation | NASDAQ:DTRTU | NASDAQ | Trust |
Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0 | - |
☒ | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
Delaware |
001-40774 |
86-3336784 | ||
(State or other jurisdiction of incorporation or organization) |
(Commission File Number) |
(I.R.S. Employer Identification Number) |
1415 West 22nd Street, Tower Floor Oak Brook, |
60523 | |||
(Address of principal executive offices) |
(Zip Code) |
Title of Each Class: |
Trading Symbol: |
Name of Each Exchange on Which Registered: | ||
Units, each consisting of one share of Class A common stock and one-half of one redeemable warrant |
DTRTU |
The Nasdaq Stock Market LLC | ||
Class A Common Stock, par value $0.0001 per share |
DTRT |
The Nasdaq Stock Market LLC | ||
Redeemable warrants, each warrant exercisable for one share of Class A common stock, each at an exercise price of $11.50 per share |
DTRTW |
The Nasdaq Stock Market LLC |
Large accelerated filer | ☐ | Accelerated filer | ☐ | |||
Non-accelerated filer |
☒ | Smaller reporting company | ☒ | |||
Emerging growth company | ☒ |
March 31, |
December 31, 202 1 |
|||||||
(unaudited) |
||||||||
Assets: |
||||||||
Current assets: |
||||||||
Cash |
$ | 166,968 | $ | 342,152 | ||||
Prepaid expenses |
770,178 | 861,218 | ||||||
|
|
|
|
|||||
Total current assets |
937,146 | 1,203,370 | ||||||
Investments held in Trust Account |
234,621,300 | 234,616,804 | ||||||
|
|
|
|
|||||
Total Assets |
$ |
235,558,446 |
$ |
235,820,174 |
||||
|
|
|
|
|||||
|
|
|
|
|
|
|
|
|
Liabilities, Class A Common Stock Subject to Possible Redemption and Stockholders’ Deficit: |
||||||||
Current liabilities: |
||||||||
Due to related parties |
$ | 11,669 | $ | 6,668 | ||||
Accounts payable |
73,606 | — | ||||||
Accrued expenses |
185,200 | 164,900 | ||||||
Franchise tax payable |
46,510 | 138,680 | ||||||
|
|
|
|
|||||
Total current liabilities |
316,985 | 310,248 | ||||||
Deferred underwriting commissions in connection with the Initial Public Offering |
8,050,000 | 8,050,000 | ||||||
Derivative warrant liabilities |
2,800,000 | 5,824,000 | ||||||
|
|
|
|
|||||
Total Liabilities |
11,166,985 | 14,184,248 | ||||||
Commitments and Contingencies |
||||||||
Class A common stock, $0.0001 par value; 23,000,000 shares subject to possible redemption at $10.20 per share at March 31, 2022 and December 31, 2021 |
234,600,000 | 234,600,000 | ||||||
Stockholders’ Deficit: |
||||||||
Preferred stock, $0.0001 par value; 1,000,000 shares authorized; none issued and outstanding |
— | — | ||||||
Class A common stock, $0.0001 par value; 380,000,000 shares authorized at March 31, 2022 and December 31, 2021 ; 23,000,000 shares issued and outstanding as of March 31, 2022 and December 31, 2021 |
— | — | ||||||
Class B common stock, $0.0001 par value; 20,000,000 shares authorized; 5,750,000 shares issued and outstanding at March 31, 2022 and December 31, 2021 |
575 | 575 | ||||||
Additional paid-in capital |
— | — | ||||||
Accumulated deficit |
(10,209,114 | ) | (12,964,649 | ) | ||||
|
|
|
|
|||||
Total Stockholders’ Deficit |
(10,208,539 | ) | (12,964,074 | ) | ||||
|
|
|
|
|||||
Total Liabilities, Class A Common Stock Subject to Possible Redemption and Stockholders’ Deficit |
$ |
235,558,446 |
$ |
235,820,174 |
||||
|
|
|
|
General and administrative expenses |
$ | 252,855 | ||
General and administrative expenses—Related Party |
5,001 | |||
Franchise tax expenses |
48,767 | |||
|
|
|||
Loss from operations |
(306,623 | ) | ||
Other income |
||||
Change in fair value of derivative warrant liabilities |
3,024,000 | |||
Interest income earned on Trust Account |
38,150 | |||
Interest income - checking |
8 | |||
|
|
|||
Total other income, net |
3,062,158 | |||
|
|
|||
Net income |
$ |
2,755,535 |
||
|
|
|||
|
|
|
|
|
Weighted average shares outstanding of Class A common stock, basic and diluted |
23,000,000 |
|||
|
|
|||
Basic and diluted net income per share, Class A common stock |
$ |
0.10 |
||
|
|
|||
Weighted average shares outstanding of Class B common stock, basic and diluted |
5,750,000 |
|||
|
|
|||
Basic and diluted net income per share, Class B common stock |
$ |
0.10 |
||
|
|
Common Stock |
Total |
|||||||||||||||||||||||||||
Class A |
Class B |
Additional Paid-in |
Accumulated |
Stockholders’ |
||||||||||||||||||||||||
Stock |
Amount |
Stock |
Amount |
Capital |
Deficit |
Deficit |
||||||||||||||||||||||
Balance - December 31, 2021 |
— |
$ |
— |
5,750,000 |
$ |
575 |
$ |
— |
$ |
(12,964,649 |
) |
$ |
(12,964,074 |
) | ||||||||||||||
Net income |
— | — | — | — | — | 2,755,535 | 2,755,535 | |||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
Balance - March 31, 2022 (unaudited) |
— |
$ |
— |
5,750,000 |
$ |
575 |
$ |
— |
$ |
(10,209,114 |
) |
$ |
(10,208,539 |
) | ||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash Flows from Operating Activities: |
||||
Net income |
$ | 2,755,535 | ||
Adjustments to reconcile net income to net cash used in operating activities: |
||||
Interest income earned on Trust Account |
(38,150 | ) | ||
Change in fair value of derivative warrant liabilities |
(3,024,000 | ) | ||
Changes in operating assets and liabilities: |
||||
Prepaid expenses |
91,040 | |||
Franchise tax payable |
(92,170 | ) | ||
Accounts payable |
73,606 | |||
Due to related parties |
5,001 | |||
Accrued expenses |
20,300 | |||
|
|
|||
Net cash used in operating activities |
(208,838 | ) | ||
|
|
|||
|
|
|
|
|
Cash Flows from Investing Activities |
||||
Withdrawal from trust for payment of franchise tax |
33,654 | |||
|
|
|||
Net cash provided by investing activities |
33,654 | |||
|
|
|||
Net change in cash |
(175,184 | ) | ||
Cash - beginning of the period |
342,152 | |||
|
|
|||
Cash - end of the period |
$ |
166,968 |
||
|
|
• | Level 1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets; |
• | Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and |
• | Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. |
For The Three Months Ended March 31, 2022 |
||||||||
Class A |
Class B |
|||||||
Basic and diluted net income per share of common stock: |
||||||||
Numerator: |
||||||||
Allocation of net income—basic and diluted |
$ | 2,204,428 | $ | 551,107 | ||||
Denominator: |
||||||||
Basic and diluted weighted average shares of common stock outstanding |
23,000,000 | 5,750,000 | ||||||
|
|
|
|
|||||
Basic and diluted net income per share of common stock |
$ | 0.10 | $ | 0.10 | ||||
|
|
|
|
Gross Proceeds |
$ | 230,000,000 | ||
Less: |
||||
Class A common stock issuance costs |
(13,245,900 | ) | ||
Plus: |
||||
Accretion of carrying value to redemption value |
17,845,900 | |||
|
|
|||
Class A common stock subject to possible redemption |
$ | 234,600,000 | ||
|
|
• | in whole and not in part; |
• | at a price of $0.01 per warrant; |
• | upon a minimum of 30 days’ prior written notice of redemption; and |
• | if, and only if, the last reported sale price (the “closing price”) of Class A common stock equals or exceeds $18.00 per share (as adjusted) for any 20 trading days within a 30-trading day period ending on the third trading day prior to the date on which the Company sends the notice of redemption to the warrant holders. |
Description |
Quoted Prices in Active Markets (Level 1) |
Significant Other Observable Inputs (Level 2) |
Significant Other Unobservable Inputs (Level 3) |
|||||||||
Assets: |
||||||||||||
Investments held in Trust Account - U.S. Treasury Securities |
$ | 234,621,300 | $ | — | $ | — | ||||||
Liabilities: |
||||||||||||
Private Placement Warrants |
$ | — | $ | — | $ | 2,800,000 |
Description |
Quoted Prices in Active Markets (Level 1) |
Significant Other Observable Inputs (Level 2) |
Significant Other Unobservable Inputs (Level 3) |
|||||||||
Assets: |
||||||||||||
Investments held in Trust Account - U.S. Treasury Securities |
$ | 234,616,804 | $ | — | $ | — | ||||||
Liabilities: |
||||||||||||
Private Placement Warrants |
$ | — | $ | — | $ | 5,824,000 |
As of March 31, 2022 |
As of December 31, 2021 |
|||||||
Exercise price |
$ | 11.50 | $ | 11.50 | ||||
Stock price |
$ | 10.03 | $ | 9.98 | ||||
Volatility |
3.5 | % | 10.0 | % | ||||
Term (years) |
5.50 | 5.50 | ||||||
Risk-free rate |
2.40 | % | 1.30 | % |
Derivative warrant liabilities at December 31, 2021 |
$ | 5,824,000 | ||
Change in fair value of derivative warrant liabilities - private |
(3,024,000 | ) | ||
Derivative warrant liabilities at March 31, 2022 |
$ | 2,800,000 | ||
Item 2. |
Management’s Discussion and Analysis of Financial Condition and Results of Operations. |
Item 3. |
Quantitative and Qualitative Disclosures About Market Risk |
Item 4. |
Controls and Procedures |
Item 1. |
Legal Proceedings |
Item 1A. |
Risk Factors |
Item 2. |
Unregistered Sales of Equity Securities and Use of Proceeds |
Item 3. |
Defaults Upon Senior Securities |
Item 4. |
Mine Safety Disclosures |
Item 5. |
Other Information |
Item 6. |
Exhibits |
* | These certifications are furnished to the SEC pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and are deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing. |
DTRT HEALTH ACQUISITION CORP. | ||
By: | /s/ Mark Heaney | |
Name: | Mark Heaney | |
Title: | Chief Executive Officer (Principal Executive Officer) |
1 Year DTRT Health Acquisition Chart |
1 Month DTRT Health Acquisition Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions